Christian Beausejour, Université de Montréal

Research

Senescence Humanized Mice Immune Cells Immunogenicity Abscopal Effect Aging Cancer Checkpoint Inhibitors

Latest papers

Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition.
Cell metabolism · 2021

All 1 publications

Latest funding

Development of improved cell therapies for the elimination of senescent cells
CIHR · 2024 · Nominated PI
$1,120,725
Integrity of the cellular transformation barriers in reprogrammed cell
NSERC · 2023 · Principal investigator
$90,000
Clearance of senescent cells to improve immune functions in aged mice
CIHR · 2019 · Nominated PI
$895,050

All 14 grants and awards

1 publications.

01

Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition.

Crespo-Garcia S, Tsuruda PR, Dejda A, Ryan RD, Fournier F, Chaney SY, Pilon F, Dogan T, Cagnone G, Patel P, Buscarlet M, Dasgupta S, Girouard G, Rao SR, Wilson AM, O'Brien R, Juneau R, Guber V, Dubrac A, Beausejour C, Armstrong S, Mallette FA, Yohn CB, Joyal JS, Marquess D, Beltran PJ, Sapieha P

Cell metabolism2021

DOI: 10.1016/j.cmet.2021.01.011 PMID: 33548171

Development of improved cell therapies for the elimination of senescent cells

Nominated PICIHR2024Project Grant

Principal investigators: Beausejour, Christian

Keywords: Humanized Mice; Immune Cells; Immunogenicity; Senescence

$1,120,725

Integrity of the cellular transformation barriers in reprogrammed cell

Principal investigatorNSERC2023Discovery Grants Program - Individual

Principal investigators: Beauséjour, Christian

Keywords: Apoptosis; DNA repair; induced pluripotent stem cells; Senescence

$90,000

Clearance of senescent cells to improve immune functions in aged mice

Nominated PICIHR2019Project Grant

Principal investigators: Beausejour, Christian

Keywords: Abscopal Effect; Aging; Cancer; Checkpoint Inhibitors; P16; Senescence; Senolytic

$895,050

Improved tumor immunotherapy using senolytic drugs.

Nominated PICIHR2018CIHR - ICR / Cancer Research Society Partnership - Research Grants

Principal investigators: Beausejour, Christian

Keywords: Tumor Immunotherapy

$60,000

Stem cell-derived Encapsulated Liver Tissue to treat liver failure without immunosuppression: technology maturation towards clinical translation

Co-investigatorCIHR2018Project Grant

Principal investigators: Paganelli, Massimiliano

Keywords: Commercialization; Liver Failure; Liver Organoids; Product Development; Regenerative Medicine; Stem Cell-Derived Tissues; Technology Transfer

$497,249

Novel Treatments for Lysosomal Neurological Disorders: Targeting Microglia Cells and Misfolded Proteins for Therapy of Mucopolysaccharidosis IIIC

Co-investigatorCIHR2017Project Grant

Principal investigators: Pshezhetsky, Alexey V

Keywords: Heparan Sulfate; Lysosomal Storage Disorders; Lysosome; Microglial Cell; Missense Mutations; Molecular Chaperones; Mucopolysaccharidosis

$715,275

Novel Treatments for Lysosomal Neurological Disorders: Targeting Microglia Cells and Missfolded Proteins for Therapy of Mucopolysaccharidosis IIIC

Co-investigatorCIHR2016Project Grant

Principal investigators: Pshezhetsky, Alexey V

Keywords: Heparan Sulfate; Lysosomal Storage Disease; Lysosome; Microglial Cell; Missense Mutations; Molecular Chaperones; Mucopolysaccharidosis

$100,000

Characterization of senescent cells fate using novel transgenic and humanized mouse models

Nominated PICIHR2015Operating Grant

Principal investigators: Beausejour, Christian

Keywords: Immunogencity; Mouse Model; Senescent Cells

$755,285

Impact des MSCs sur la croissance tumorale dans un modèle humanisé

SupervisorCIHR2015Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Principal investigators: Moquin-Beaudry, Gaël

Keywords: Cellules Souches; Souris Humanisées; Tumorigenèse

$105,000

An autologous cell therapy approach to treat Duchenne muscular dystrophy using engineered muscle tissue derived from induced pluripotent stem cells.

Nominated PICIHR2012Operating Grant

Principal investigators: Beausejour, Christian

Keywords: Cell Therapy; Gene Therapy; Immunogenecity; Ipsc; Muscular Dystrophy; Myoblastes; Zinc Finger Nuclease

$596,320

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Physiology and Pharmacology
Pathologie et biologie cellulaire
Pediatrics
Ophthalmology
Engineering Physics

Co-authors at Université de Montréal, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.

Przemyslaw Sapieha

Engineering Physics

1 shared papers, latest 2021

Przemyslaw Sapieha

Ophthalmology

1 shared papers, latest 2021

Jean-Sébastien Joyal

Pediatrics

1 shared papers, latest 2021

Alexandre Dubrac

Pathologie et biologie cellulaire

1 shared papers, latest 2021

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Mention their CIHR grant from 2024

Subject: Prospective PhD student: Senescence Dear Professor Beausejour, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition." (2021), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Development of improved cell therapies for the elimination of senescent cells" (2024), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]